Management of cytomegalovirus infection in solid organ transplantation (Q37803335)

23 August 2017

Management of cytomegalovirus infection in solid organ transplantation (English)

1 reference

23 August 2017

0 references

organ transplantation

1 reference

inferred from title

cytomegaloviral disease

1 reference

inferred from title

author

Camille Nelson Kotton

object named as

Camille N Kotton

series ordinal

1

0 references

language of work or name

English

0 references

publication date

26 October 2010

1 reference

Nature Reviews Nephrology

23 August 2017

1 reference

23 August 2017

6

1 reference

23 August 2017

12

1 reference

23 August 2017

711-721

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.141

23 August 2017

0 references

cites work

Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

KDIGO clinical practice guideline for the care of kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Infection in solid-organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus infection renal transplant recipients: risk factors and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Hypogammaglobulinemia in lung transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Association between a polymorphism in the human programmed death-1 (PD-1) gene and cytomegalovirus infection after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Benefits of cytomegalovirus prophylaxis in solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Acceleration of allograft failure by cytomegalovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The 'indirect' effects of cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

CMV infection, diagnosis and antiviral strategies after liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Monitoring human cytomegalovirus infection in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Detection of CMV DNA: is EDTA whole blood superior to EDTA plasma?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Interlaboratory comparison of cytomegalovirus viral load assays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Quantification of Cytomegalovirus DNA in BAL Fluid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Preemptive Therapy for Systemic and Pulmonary Human Cytomegalovirus Infection in Lung Transplant Recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Definitions of cytomegalovirus infection and disease in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cellular immune responses to cytomegalovirus in renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Differences in CMV-Specific T-Cell Levels and Long-Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Immunobiology of human cytomegalovirus: from bench to bedside.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Vaccine prevention of maternal cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Less pessimistic long-term results for patients with cytomegalovirus disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Delayed-onset primary cytomegalovirus disease after liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus drug resistance and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Relapsing cytomegalovirus infection in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Ganciclovir-resistant cytomegalovirus in organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Human cytomegalovirus resistance to antiviral drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Update in management of ganciclovir-resistant cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.141

Immunosuppressive effects of beta-herpesviruses

31 March 2020

1 reference

12 December 2020

Cytomegalovirus infection and survival in lung transplant recipients

1 reference

12 December 2020

VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection

1 reference

12 December 2020

Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients

1 reference

12 December 2020

Monitoring of human cytomegalovirus, HHV-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: a prospective study.

1 reference

12 December 2020

A survey of CMV prevention strategies after liver transplantation

1 reference

12 December 2020

Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays

1 reference

12 December 2020

Epidemiology of cytomegalovirus infections

1 reference

12 December 2020

Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation

1 reference

12 December 2020

Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.141

1 reference

23 August 2017

1 reference

PubMed ID

20978468